



WORLD ORGANISATION FOR ANIMAL HEALTH  
*Protecting animals, preserving our future*



# Rapid Fluorescent Focus Inhibition Test (RFFIT):

- \*Strains of virus
- \*Infection of cell culture
- \*Harvesting & Titration of virus

Shrikrishna Isloor \*, Dilip, L., G. Kavitha

\*Professor & Lab. Director,  
KVAFSU-CVA Rabies Diagnostic Laboratory,  
OIE Reference Lab. for Rabies,  
Dept. of Microbiology, Veterinary college,  
Hebbal, Bengaluru

**OIE Virtual Training Series on Rabies Serology for  
SAARC Region**

11-13 October 2021, 2 PM Japan Time (GMT+9)

# Rapid Fluorescent Focus Inhibition Test (RFFIT)

- RFFIT- virus neutralization (VN) test
  - **Detecting rabies virus neutralizing antibodies**
- Residual virus detected using fluorescence microscope

## Application:

- Determining immune responses to vaccination
- International Pet travel
- Monitoring mass vaccination campaigns in dogs










# Principle of RFFIT

## Similar to Haemagglutination inhibition

- Two fold dilutions of **test serum** + fixed amount (100 TCID<sub>50</sub>) CVS
- Neutralization detected by inoculating cell culture.
- Presence or absence of virus - **DFA**.

**HI**


|   | Components              | Interaction   | Microtiter Results   |
|---|-------------------------|---|--|
| A | RBCs                    |  | No Reaction<br>                 |
| B | Virus + RBCs            |  | Hemagglutination<br>            |
| C | Virus + Antibody + RBCs |  | Hemagglutination Inhibition<br> |



- Recording **highest serum dilution at which 100% of the challenge inoculum neutralized** – No fluorescence.
- Titre of neutralizing antibody in test serum (in IU/ml) obtained by comparison with the titre of ref. serum.

# Strains of virus, infection of cell culture, harvesting and titration of virus used for RFFIT


## Strains of rabies virus used for RFFIT-



1. PV 3462 (Dr. Larghi's) strain - Pasteur Institute of India, Coonoor

2. CVS-11 strain - NIMHANS, Bengaluru

- Seed virus stored at  $-80 \pm 2$  °C
- Aliquot from seed lot grown, harvested and titrated.
- **Avoid repeat freezing - thawing**



## Infection of cell culture

- BHK 21 cells with 80 % monolayer - used for inoculation of seed virus
- Monolayer seeded with Rabies virus - 37 °C in 5 % CO<sub>2</sub> - viral adsorption for 90 mins
- Remove viral inoculum – Add growth medium (GM) incubated at 37 °C in CO<sub>2</sub> for 48 hrs.



# Estimation of virus inoculum to be seeded:

Volume of virus stock to be added =  $\frac{\text{multiplicity of infection (MOI)} \times \text{number of cells}}{\text{Virus titre}}$

BHK cells infected with rabies virus at a multiplicity of infection (MOI) of 0.1.

## Harvesting of virus

Virus harvested in a cryovial, aliquoted and stored in  $-80^{\circ}\text{C}$ .


**Titration of the harvested virus** - To estimate the infectious unit of virus

### Procedure:

Harvested virus 10 fold serially diluted GM

(Log dilutions from  $10^{-1}$  to  $10^{-6}$ )


| Tube no. | 1                 | 2                   | 3                 | 4                 | 5                 | 6                 |
|----------|-------------------|---------------------|-------------------|-------------------|-------------------|-------------------|
| Virus    | 100 $\mu\text{l}$ | 10x serial dilution | →                 |                   |                   |                   |
| Diluent  | 900 $\mu\text{l}$ | 900 $\mu\text{l}$   | 900 $\mu\text{l}$ | 900 $\mu\text{l}$ | 900 $\mu\text{l}$ | 900 $\mu\text{l}$ |
| Dilution | $10^{-1}$         | $10^{-2}$           | $10^{-3}$         | $10^{-4}$         | $10^{-5}$         | $10^{-6}$         |



Five wells for each dilution (5 replicates).

Virus dilutions  $10^{-1}$  to  $10^{-6}$  added into columns 1-6 (100  $\mu$ L)

**Table 1: Layout of microtitre plate for virus titration**



|   | 1         | 2         | 3         | 4         | 5         | 6         |    |    |  |  |  |  |
|---|-----------|-----------|-----------|-----------|-----------|-----------|----|----|--|--|--|--|
|   | $10^{-1}$ | $10^{-2}$ | $10^{-3}$ | $10^{-4}$ | $10^{-5}$ | $10^{-6}$ |    |    |  |  |  |  |
| A |           |           |           |           |           |           | CC | VC |  |  |  |  |
| B |           |           |           |           |           |           | CC | VC |  |  |  |  |
| C |           |           |           |           |           |           | CC | VC |  |  |  |  |
| D |           |           |           |           |           |           | CC | VC |  |  |  |  |
| E |           |           |           |           |           |           | CC | VC |  |  |  |  |
|   |           |           |           |           |           |           |    |    |  |  |  |  |
|   |           |           |           |           |           |           |    |    |  |  |  |  |
|   |           |           |           |           |           |           |    |    |  |  |  |  |

50  $\mu$ L of BHK- 21



Cell control (CC)- 50  $\mu$ L BHK 21 with 100  $\mu$ L of GM



Virus control (VC) - 50  $\mu$ L of BHK 21 +100  $\mu$ L of neat virus with GM



5 % CO<sub>2</sub> at 37 °C  $\pm$  1 °C for 48 hrs.

**Acetone fixation:** - Supernatant removed - 100  $\mu$ L of 70 % chilled acetone added.


-20  $^{\circ}$ C freezer for 60 min.

**Addition of FITC conjugate:** acetone removed & plate air dried for 5 min.

50  $\mu$ L of (1:15  $\pm$  1:5) anti-rabies **N-protein Mab FITC conjugate**

37  $^{\circ}$ C for 60  $\pm$  5 minutes.

**Washing of plates:** Contents discarded and washed (1x PBS) twice




## Observation (10X and 20X objectives)

All the fields in each well

Presence or absence of viral inclusions as **apple green** fluorescent particles.

The observations at various dilutions of virus documented (Table 1): two faculties to approve



Virus control



Cell Control



## Interpretation of results:

Reed-Muench method (1938) in terms of TCID<sub>50</sub>.

| Virus dilution   | Infection ratio | Infected | Uninfected | Accumulated values |                | Infection ratio (I/I + U) | Percent (I/I+U)*100 |
|------------------|-----------------|----------|------------|--------------------|----------------|---------------------------|---------------------|
|                  |                 |          |            | Infected (I)       | Uninfected (U) |                           |                     |
| 10 <sup>-1</sup> | /5              |          |            |                    |                |                           |                     |
| 10 <sup>-2</sup> | /5              |          |            |                    |                |                           |                     |
| 10 <sup>-3</sup> | /5              |          |            |                    |                |                           |                     |
| 10 <sup>-4</sup> | /5              |          |            |                    |                |                           |                     |
| 10 <sup>-5</sup> | /5              |          |            |                    |                |                           |                     |
| 10 <sup>-6</sup> | /5              |          |            |                    |                |                           |                     |

The 50% end point considered for infection. The Proportionate Distance (PD) is calculated as below:

$$\text{Proportionate Distance (PD)} = \frac{\text{Infectivity above 50 \% - 50}}{\text{Infectivity above 50\% - Infectivity below 50 \%}}$$

log dilution above 50 per cent considered. Hence, the 50 per cent end point is calculated in the following way:

$$(\log \text{ID}_{50}) = (\log \text{dilution above 50 per cent}) + (\text{Proportionate Distance} \times \log \text{dilution factor})$$

**TCID<sub>50</sub> calculated as  $10^{-x} / 0.1$  ml**

End point dilution : Highest dilution that infects 50 per cent of the test units inoculated - **one TCID<sub>50</sub>**.

**100 TCID<sub>50</sub> =  $10^{-(x-2)} / 0.1$  ml**

Antilog (x-2) is the dilution factor.

Original virus stock is diluted by {antilog (x-2)} times to get 100 TCID<sub>50</sub> virus.

100 TCID<sub>50</sub> virus used in RFFIT

# Rapid Fluorescent Focus Inhibition Test (RFFIT)- Methodology

## Materials and equipment

- Test serum samples
- BHK-21 cell lines
- Titrated virus lots of PV 3462 (Dr. Larghi's) strain or CVS-11 of rabies virus
- 96-well tissue culture plate
- GM
- PBS pH 7.2±0.2
- Variable channel Micro-pipettes (1-10 µl, 20-100 µl and 20-1000 µl)
- Sterile disposable microtips (1-10µl, 20-200µl and 1000µl)
- Sterile Petri plates
- BSC
- Reference anti-rabies serum: ERIG
- CO<sub>2</sub> incubator
- Inverted Microscope with fluorescence attachment
- Anti-rabies nucleoprotein IgG FITC conjugate
- 70 % Chilled acetone with double distilled water

# RFFIT - Procedure

Preparation of BSC



Heat inactivation of serum samples at  $56 \pm 2$  °C for 30-32 min.



RFFIT microtiter plate layout



| Sample No | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     | 9     | 10    | Ref.S       | Controls |
|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|----------|
| A         | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2 Ref.S   | VC       |
| B         | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4 Ref.S   | VC       |
| C         | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8 Ref.S   | VC       |
| D         | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16 Ref.S  | VC       |
| E         | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32 Ref.S  | CC       |
| F         | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64 Ref.S  | CC       |
| G         | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 Ref.S | CC       |
| H         | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 Ref.S | CC       |




100 µL of GM to sample, Ref. and VC wells  
200 µL of GM added to CC wells .

100 µL of test serum added - to the first well (1:2) and mixed.

Mixed, 100 µL from first well transferred to second well (1:4) and similar serial dilutions upto 8<sup>th</sup> well (1:256)  
100 µL discarded from the eighth well.  
Similarly , 2 fold dilutions of reference serum (eRIG) made.

| Sample No | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     | 9     | 10    | Ref.S       | Controls |
|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------------|----------|
| A         | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2   | 1:2 Ref.S   | VC       |
| B         | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4   | 1:4 Ref.S   | VC       |
| C         | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8   | 1:8 Ref.S   | VC       |
| D         | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16  | 1:16 Ref.S  | VC       |
| E         | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32  | 1:32 Ref.S  | CC       |
| F         | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64  | 1:64 Ref.S  | CC       |
| G         | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 | 1:128 Ref.S | CC       |
| H         | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 | 1:256 Ref.S | CC       |








100 $\mu$ L of 100 TCID<sub>50</sub> of virus added to all wells – Except CC wells

5% CO<sub>2</sub> for 60-65 min at 37 $\pm$ 1  $^{\circ}$ C

BHK-21 (80-90%) in T-25 flask trypsinized by using trypsin-EDTA in GM.

50  $\mu$ L of BHK 21 added to each well



Incubated at 5% CO<sub>2</sub> for 48 hours at 37 $\pm$ 1  $^{\circ}$ C

**Acetone fixation:** supernatant removed - 100  $\mu$ L of 70 % chilled acetone added.





-20 °C freezer for 60 min.



**Addition of FITC conjugate:** acetone removed & plate air dried for 2-5 minutes.




50  $\mu$ L (1:15  $\pm$  1:5) anti-rabies **N-protein Mab FITC conjugate** added.



37 °C for 60  $\pm$  5 min.

**Washing** : Contents discarded and washed ( 1x PBS ) 3x

Observed under 10X and 20X objectives of flu.



VC




Cliquez pour ajouter du  
texte




CC

Sample reading



1:2 serum dilution




1:4 serum dilution




1:8 serum dilution




1:16 serum dilution




1:32 serum dilution



1:64 serum dilution



1:128 serum dilution



1:256 serum dilution

Result: 4.0 IU/ml